Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Market Catalysts host Julie Hyman takes a closer look at some of the trending tickers during Tuesday's trading session.

(Reuters) - Pfizer on Tuesday lifted its full-year profit forecast for the second time in a row as robust demand for its blockbuster heart treatment and blood thinner helped it post third-quarter ...

Nov 5 (Reuters) - Pfizer (PFE.N) plans to sweeten its bid for Metsera (MTSR.O), a person familiar with the matter told ...

Jon Smith explains why investors can look across the pond for stocks with attractive dividend forecasts and shares a specific ...

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales ...